The hormone melatonin phase shifts circadian rhythms generated by the mammalian biological clock, the suprachiasmatic nucleus (SCN) of the hypothalamus, through activation of G protein-coupled MT 2 melatonin receptors. This study demonstrated that pretreatment with physiological concentrations of melatonin (30 -300 pM or 7-70 pg/mL) decreased the number of hMT 2 melatonin receptors heterologously expressed in mammalian cells in a time and concentration-dependent manner. Furthermore, hMT 2 -GFP melatonin receptors heterologously expressed in immortalized SCN2.2 cells or in non-neuronal mammalian cells were internalized upon pretreatment with both physiological (300 pM or 70 pg/mL) and supraphysiological (10 nM or 2.3 ng/mL) concentrations of melatonin. The decrease in MT 2 melatonin receptor number induced by melatonin (300 pM for 1 h) was reversible and reached almost full recovery after 8 h; however, after treatment with 10 nM melatonin full recovery was not attained even after 24 h. This recovery process was partially protein synthesis dependent. 
The hormone melatonin is released primarily from the pineal gland following a circadian rhythm with high levels at night and low levels during the day. The synthesis of melatonin is regulated by the biological clock in the suprachiasmatic nucleus (SCN) of the hypothalamus. In turn, pineal melatonin modulates clock function through a direct action on G-proteincoupled MT 1 and MT 2 melatonin receptors in the SCN (1) . Both the mRNA and protein for MT 1 melatonin receptors have been reported in the mammalian SCN (2) (3) (4) (5) . Physiologically, melatonin acutely inhibits neuronal firing in the SCN through the MT 1 melatonin receptor, as this action is absent in mice with targeted deletion of the MT 1 melatonin receptor (6) . Similarly, both the MT 2 melatonin receptor mRNA and protein have been localized in the mammalian SCN (3) (4) (5) . In contrast to the MT 1 melatonin receptor, the MT 2 receptor protein in the SCN is expressed at such a low level that it is undetectable by 2-[ 125 I]-iodomelatonin binding (3, 6, 7) . There is, however, a clear physiological role for this receptor in the mammalian SCN.
Melatonin through activation of the MT 2 melatonin receptor phase-shifts circadian rhythms generated within the SCN both in vivo and in vitro as this response is blocked by the selective MT 2 melatonin receptor antagonist 4P-PDOT (3, 4) . Furthermore, in the rat SCN and immortalized SCN2.2 cells activation of the MT 2 melatonin receptor by melatonin stimulates PKC activity (4, 5) . Taken together these studies demonstrate the existence of functionally active MT 1 and MT 2 melatonin receptors in the mammalian SCN.
Several studies reported direct melatonin-mediated regulation of endogenous MT 1 melatonin receptors. In the rat SCN, specific 2-[ 125 I]-iodomelatonin binding, primarily to MT 1 receptors, follows a diurnal rhythm with low levels during the night, while melatonin directly decreases the density of MT 1 melatonin receptors (8, 9) . In GT1-7 neurons, endogenous MT 1 melatonin receptors internalize after short-term exposure to melatonin (10) . Melatonin-mediated regulation of endogenous MT 2 melatonin receptors has not been examined because the low level of expression of this receptor in native tissues makes analysis difficult. As such, melatonin-mediated regulation of the MT 2 melatonin receptor has been restricted to recombinant systems in which the receptor is overexpressed. Melatonin desensitizes and internalizes MT 2 melatonin receptors after exposure to supraphysiological concentrations of melatonin (11, 12) . The role of physiological concentrations of melatonin regulating MT 2 melatonin receptors has not been elucidated.
Evidence suggests that melatonin may in fact desensitize endogenous MT 2 melatonin receptors in the SCN. In a rat in vitro SCN brain slice model, melatonin through activation of endogenous MT 2 melatonin receptors phase-shifts circadian rhythms of neuronal firing when administered either at dawn or dusk (3, 4, 13) . In contrast, melatonin phase-shifts the circadian rhythm of rat locomotor activity in vivo only when administered at dusk (14) . The reason for this discrepancy is unknown, but the lack of a phase shift by melatonin at dawn in vivo could be attributed to desensitization of MT 2 melatonin receptors by the nocturnal surge of endogenous melatonin, which is not present in the in vitro SCN brain slice model.
In the present study, we investigated melatoninmediated regulation of MT 2 melatonin receptors by physiological concentrations of melatonin. Neuronal and non-neuronal mammalian cells expressing recombinant hMT 2 melatonin receptors were used to determine the mechanism(s) by which physiological concentrations of melatonin regulate receptor internalization and recovery. In parallel, both the native rat SCN brain slice and immortalized rat SCN2.2 cells expressing endogenous MT 2 melatonin receptors were used to determine changes in the functional sensitivity of this receptor upon pretreatment with physiological concentrations of melatonin mimicking the nocturnal surge.
MATERIALS AND METHODS

Materials
cDNA containing the complete coding region of the hMT 1 (15) .
Cell culture
Chinese hamster ovary (CHO) cells
CHO cell cultures were grown as monolayers in F12 media supplemented with 10% fetal calf serum, penicillin (100 units/mL) and streptomycin (100 g/mL) in 5% CO 2 at 37°C. Generation of hMT 1 or hMT 2 melatonin receptor fusion proteins expressing an amino-terminal FLAG epitope and in some cases a carboxyl-terminal green fluorescence protein (GFP) epitope, as well as CHO cells stably expressing hMT 2 -FLAG receptors (CHO-MT 2 ) has been described previously (12) . The density of MT 2 melatonin receptors in the CHO-MT 2 cell line was 320 Ϯ 111 fmol/mg protein (nϭ3). For transient expression of hMT 2 -FLAG-GFP receptors, CHO cells at 40 -50% confluency were transiently transfected with the corresponding constructs using Effectene (Qiagen).
Rat immortalized SCN2.2 cells
SCN2.2 cells were maintained in minimal essential medium (Mediatech, Herndon, VA, USA) supplemented with 10% (vol/vol) fetal bovine serum, 2 g/mL glucose, penicillin (100 U/mL) and streptomycin (0.1 mg/mL). Cells were propagated continuously at 37°C under a humidified 5% CO 2 : 95% air mixture, grown to confluence and passed every 3 days. Media was changed every 48 h. Experiments were carried out on cells between the 17th and 35th passage. For transient expression of hMT 1 -FLAG, hMT 2 -FLAG, or hMT 2 -FLAG-GFP receptors, SCN2.2 cells at 80 -90% confluency were transfected with Lipofectamine 2000 (Invitrogen).
Membrane preparation and 2-[
125 I ]-iodomelatonin binding studies CHO or SCN2.2 cells were washed twice with phosphatebuffered saline (PBS) on ice for 5 min, lifted in potassium phosphate buffer (10 mM, pH 7.4) containing sucrose (0.25 M) and EDTA (1 mM), then pelleted by centrifugation. Cell pellets were then resuspended in Tris-HCl (50 mM, pH 7.4; MgCl 2 10 mM) and collected by centrifugation (13,800 g). Membrane pellets were stored at -80°C until used. 2-[
125 I ]-Iodomelatonin binding was determined in cell membranes (10 -40 g protein/assay) as described previously (16) . Binding reactions were started by adding cell membranes to tubes containing binding buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 ), 2-[ 125 I ]-iodomelatonin (ϳ100 pM, unless otherwise stated) and appropriate concentrations of vehicle or competing agents in a total assay volume of 0.26 mL. After incubations for 1 h at 25°C, reactions were terminated by rapid vacuum filtration through glass fiber filters (Schleicher and Schuell No. 30) soaked in 0.5% polyethylenimine solution. Nonspecific binding was determined in the presence of 1 M melatonin.
Confocal microscopy
CHO cells in culture at 40 -50% confluency were transiently transfected with hMT 2 -FLAG-GFP melatonin receptors using the Effectene transfection kit (Qiagen). SCN2.2 cells in culture at 80 -90% confluency were transiently transfected with hMT 2 -FLAG-GFP melatonin receptors using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, CHO or SCN2.2 cells were plated on poly-d-lysinecoated coverslips. One day later, cells were incubated in serum-free media (F12 media for CHO and N2 media for SCN2.2) for 5 h before and during treatments, washed once in PBS, then treated with vehicle or melatonin, as appropriate. Cells were then washed once with PBS for 5 min, fixed with 4% paraformaldehyde for 7.5 min, and incubated with wheat germ agglutinin/Texas Red conjugate (2 g/mL) for 30 min at room temperature. Subsequently, cells were incubated with 4% paraformaldehyde for 20 min at room temperature and washed twice with PBS. Coverslips were then mounted with Slowfade antifade reagent (Molecular Probes) and visualized on an Olympus confocal microscope.
PKC assay
SCN2.2 cells were plated (4.0ϫ10 4 cells/cm 2 ) at circadian time (CT) 10 on 12-well plates precoated with poly-d-lysine. The time of plating was denoted as CT10 based on previous comparisons between the rhythms of glucose utilization and brain-derived neurotrophic factor content in immortalized SCN2.2 cells and the SCN in vivo (17, 18) . After 54.5 h (ϳ80% confluency), cells were serum starved for 1 h, then pretreated in serum-free media for 8 h (CT17.5-CT1.5) with either vehicle or 300 pM melatonin in the absence or presence of 4P-PDOT (10 nM). After the pretreatment, cells were washed with PBS and incubated for 0.5 h in serum-free media. Cells were then stimulated with vehicle or melatonin (1 nM) at CT2 for 10 min. PKC activity was determined by incorporation of [␥ 32 P]ATP into a synthetic substrate peptide corresponding to amino acids residues 4-14 of myelin basic protein in accordance with manufacturer's protocol (Upstate Biotechnology, Lake Placid, NY, USA).
Extracellular recordings from the rat SCN brain slice SCN brain slices were prepared and extracellular recordings performed following procedures described by Hunt et al. (4) . Male Long-Evans rats (8-to 12-wk-old) were maintained in a 12/12 light/dark cycle with free access to food and water. Rats were decapitated during the light period (between CT1-CT9), and the brain quickly dissected and blocked. A 500 m coronal brain slice containing the SCN was placed in a recording chamber and continuously perfused with Earle's balanced salt solution supplemented with 24.6 mM glucose, 26.2 mM sodium bicarbonate and 5 mg/L gentamicin and saturated with 95% O 2 -5% CO 2 at 37°C. A glass electrode filled with 5 M NaCl was used to sample cells throughout the SCN. Each cell was monitored for 4 min, the action potentials grouped into 10 s bins, and the mean firing rate determined for each cell. Mean firing rates were grouped into 2 h bins and smoothed by plotting the data as 15 min running averages. Data were collected using customized LabVIEW software (National Instruments, Austin, TX, USA). The peak in the circadian rhythm of neuronal firing was visually determined. Brain slices were pretreated for 8 h (CT14.5-CT22.5) with either vehicle or melatonin (300 pM) in the absence or presence of 4P-PDOT (100 nM), which was added from CT14 to CT22.5. After a 0.5 h washout period, slices were stimulated at CT23 with either vehicle or melatonin (1 nM) applied by a 1 L microdrop for 10 min.
Data analysis and statistics
Percent decreases in specific 2-[
125 I ]-iodomelatonin binding were calculated by dividing the average specific binding (fmol/mg protein) after treatment with a defined melatonin concentration by the average specific binding (fmol/mg protein) of the vehicle-treated control. Statistical significance was determined by either an unpaired Student's t test for comparisons between two groups, or 1-or 2-way ANOVA with Bonferroni post hoc test for multiple comparisons. A value of P Ͻ0.05 was taken as statistically significant.
RESULTS
Physiological concentrations of melatonin decreased the number of hMT 2 melatonin receptors heterologously expressed in mammalian cells
Pretreatment of CHO-MT 2 cells with melatonin significantly decreased specific 2-[
125 I ]-iodomelatonin binding in a time-(10 -480 min) and concentration-(30 pM-10 nM) dependent manner ( Fig. 1) . A physiological diurnal concentration of melatonin (30 pM or 7 pg/mL) mimicking daytime levels significantly decreased specific 2-[ 125 I ]-iodomelatonin binding after 8 h by 44.6 Ϯ 8.3% (nϭ3, PϽ0.05), while a melatonin concentration (300 pM or 70 pg/mL) mimicking nighttime levels significantly decreased binding after 1 h by 63.0 Ϯ 1.3% (nϭ3, PϽ0.001) compared with vehicletreated, time-matched controls ( Fig. 1) . Supraphysiological concentrations of melatonin (1-10 nM or 0.23-2.3 ng/mL) significantly decreased specific 2-[ 125 I ]-iodomelatonin binding after 1 h and 10 min exposure, respectively (Fig. 1) .
The time course of MT 2 melatonin receptor recovery after exposure to melatonin was determined in CHO-MT 2 cells pretreated with a physiological (300 pM for 1 h) or a supraphysiological (10 nM for 10 min) concentration of melatonin. After pretreatment of CHO-MT 2 cells with 300 pM melatonin, incubation in melatonin-free media led to a significant recovery in specific 2-[
125 I ]-iodomelatonin binding after 8 h washout (97.5Ϯ16.4%, nϭ5, PϽ0.01) and continued until reaching a plateau at 24 h (121.8Ϯ3.8%, nϭ3, PϽ0.001) ( Fig. 2A) . Similarly, a significant recovery after pretreatment with 10 nM melatonin was observed after 8 h washout (56.6Ϯ0.7%, nϭ3, PϽ0.05), but recovery was only 86.7 Ϯ 2.8% (nϭ3, PϽ0.001) after 24 h (Fig. 2B) .
To assess whether recovery of specific 2-[ (Fig. 2C) . Similarly, after pretreatment with 10 nM melatonin, specific 2-[ 125 I ]-iodomelatonin binding was reduced by 85.9 Ϯ 3.0% (nϭ4), but recovery after 16 h reached only 48.3 Ϯ 8.0% (nϭ6, PϽ0.01) (Fig. 2D) . In the presence of cycloheximide, specific 2-[ 125 I ]-iodomelatonin binding recovered to only 27.0 Ϯ 3.5% (nϭ6, PϽ0.05) (Fig. 2D) .
Effect of melatonin pretreatment on the trafficking of hMT 2 melatonin receptors heterologously expressed in mammalian cells
CHO cells were transiently transfected with hMT 2 melatonin receptors containing an amino-terminal FLAG epitope and a carboxyl-terminal GFP sequence (MT 2 -GFP). The FLAG or GFP epitopes did not affect receptor binding or function (12) . Cells were serum starved for 5 h, then treated with 10 nM melatonin for 10, 60, 180, or 480 min (Fig. 3) . Receptors were localized by overlay of the GFP-tagged MT 2 melatonin receptors with cells co-stained with wheat germ agglutinin/Texas Red (labels cell surface plasma membrane). In vehicletreated cells (0 min), the MT 2 melatonin receptors were localized to the cell surface plasma membrane and perinuclear regions (Fig. 3) . Melatonin (10 nM) treatment for 10 min appeared to increase the intracellular fluorescence (Fig. 3) . Furthermore, pretreatment with this concentration for 1, 3 and 8 h not only appeared to increase the intracellular fluorescence but also induced the formation of large intracellular puncta compared with vehicle-treated controls, with a concomitant decrease in MT 2 -GFP receptor membrane localization (Fig. 3) . More important, pretreatment with a physiological concentration of melatonin (300 pM for 8 h) increased the intracellular fluorescence and induced the formation of large intracellular puncta compared with vehicle-treated controls (Fig. 4) like and large glial-like cells (Fig. 6) (15) . MT 2 melatonin receptors were expressed on the cell surface and in perinuclear regions of both neuronal-like and glial SCN2.2 cells, as observed by colocalization of MT 2 -FLAG-GFP receptors with wheat germ agglutinin/ Texas Red (Fig. 6A, C) . Pretreatment with a concentration of melatonin (300 pM) mimicking the nocturnal hormonal surge (8 h) increased the intracellular fluorescence and induced the formation of large intracellular puncta with a concomitant reduction of cell surface residency (Fig. 6B, D) . Pretreatment of SCN2.2 cells with 10 nM melatonin for 1 h also internalized MT 2 melatonin receptors in both glial and neuronallike cells (data not shown).
Effect of pretreatment with nocturnal physiological levels of melatonin on the functional sensitivity of endogenous MT 2 melatonin receptors in rat immortalized SCN2.2 cells
In rat immortalized SCN2.2 cells, basal PKC activity shows a diurnal rhythm with nadirs during subjective day at CT10 and CT2 (19) . At these periods of sensitivity, when PKC activity is at the lowest (19) melatonin stimulates PKC activity through activation of MT 2 melatonin receptors (4, 19) . We used this model to assess whether physiological concentrations of melatonin mimicking the nocturnal duration in vivo, desensitized the MT 2 melatonin receptor-mediated activation of PKC at CT2. A melatonin (1 nM) pulse at CT2 stimulated PKC phosphotransferase activity to 0.94 Ϯ 0.14 pmol·min -1 ·g protein -1 (nϭ13, PϽ0.05) compared with vehicle control (0.61Ϯ0.08 pmol·min -1 ·g protein -1 , nϭ13) (Fig. 7A) . Melatonin-mediated stimulation of PKC phosphotransferase activity at CT2 was significantly reduced (PϽ0.05) after pretreatment with 300 pM melatonin for 8 h (CT17.5-CT1.5) (Fig. 7B) . We next used the selective and competitive MT 2 melatonin receptor antagonist 4P-PDOT (10 nM) (3, 4) to assess whether the melatonin-mediated desensitization was mediated through activation of the MT 2 receptor. 4P-PDOT when used alone (CT17.5-CT1.5) or in combination with melatonin (300 pM) for 8 h (CT17.5-CT1.5) did not affect basal phosphotransferase activity at CT2 (Fig. 7A, B) . Pretreatment with 4P-PDOT (10 nM) alone did not affect melatonin-mediated stimulation of phosphotransferase activity (Fig. 7B) . After combined pretreatment of 4P-PDOT (10 nM) and melatonin (300 pM) for 8 h, a melatonin pulse (1 nM, CT2) significantly stimulated phosphotransferase activity (Fig. 7B) . 
Effect of pretreatment with nocturnal physiological levels of melatonin on the functional sensitivity of endogenous MT 2 melatonin receptors in the rat SCN brain slice
We next studied the functional sensitivity of endogenous MT 2 melatonin receptors in the rat SCN brain slice after exposure to physiological concentrations of melatonin mimicking the nocturnal duration of hormone release in vivo. The functional sensitivity of the MT 2 receptor after various pretreatments was assessed by the ability of melatonin to shift the peak of the circadian rhythm of neuronal firing in the rat SCN brain slice (4, 13, 20) . In controls, a vehicle pulse at CT23 after pretreatment with vehicle during subjective night did not affect the circadian rhythm of neuronal firing as the peak was observed at CT 6.8 Ϯ 0.1 (nϭ3) (Fig. 8A, Fig. 9) . In contrast, a melatonin (1 nM) pulse applied as a microdrop to the SCN slice at CT23 advanced the peak of the circadian rhythm of neuronal firing to CT 3.2 Ϯ 0.2 (nϭ3) (Fig. 8B vs. A, Fig. 9 ). A vehicle pulse at CT23 after pretreatment with 300 pM melatonin for 8 h (CT14.5-CT22.5) did not affect the circadian rhythm of neuronal firing (Fig. 8C vs. A; Fig.  9 ). However, in SCN slices pretreated with 300 pM melatonin for 8 h (CT14.5-CT22.5) the phase advance induced by melatonin (1 nM) at CT23 was prevented as the peak position (CT 6.6Ϯ0.2, nϭ3) (Fig. 7D) was not significantly different from control (Fig. 8C, Fig. 9 ). In addition, preincubation with 1 nM melatonin during 8 h also prevented melatonin-mediated phase advance by 1 nM melatonin applied at CT23 (data not shown).
To determine whether the lack of phase shift after pretreatment with physiological concentrations of melatonin during subjective night was due to activation of MT 2 melatonin receptors we used the MT 2 selective and competitive melatonin receptor antagonist, 4P-PDOT (3, 4) . Incubation with the selective MT 2 antagonist 4P-PDOT (100 nM) alone for 8.5 h (CT14 -CT22.5) did not affect the position of the peak of neuronal firing upon a vehicle pulse at CT23 (CT 6.8Ϯ0.15, nϭ3) (Fig. 8E vs. A, Fig. 9 ) or the phase advance induced by melatonin (3.5Ϯ0.15 h) (Fig. 8F  vs. B, Fig. 9 ). Coincubation with the selective MT 2 antagonist 4P-PDOT during pretreatment with 300 pM melatonin for 8 h (CT14.5-CT22.5) did not affect the position of the peak of neuronal firing after a vehicle pulse (Fig. 8G vs. E, Fig. 9 ). This treatment, however, did not prevent the phase advance induced by melatonin (1 nM) at CT23 as the peak position was at CT 2.8 Ϯ 0.1 (nϭ3) (Fig. 8H vs. 8F, Fig. 9 ).
DISCUSSION
This study demonstrates that physiological concentrations of melatonin mimicking the nocturnal surge desensitize endogenous MT 2 melatonin receptors expressed in the rat SCN. The melatonin-mediated internalization of recombinant MT 2 melatonin receptors expressed in mammalian cells was time and concentration dependent. This decrease in MT 2 melatonin receptor number was partially recoverable and dependent on new protein synthesis. Similarly, pretreatment with physiological concentrations of melatonin functionally desensitized endogenous MT 2 melatonin receptors in an immortalized SCN2.2 cell line as determined by the activation of PKC stimulation at CT2 and in the rat SCN, as determined by the ability of melatonin to phase-shift the circadian rhythm of neuronal firing at CT23. We conclude that physiological concentrations of melatonin mimicking the nocturnal secretion of the hormone in vivo desensitize endogenous MT 2 melatonin receptors in the rat SCN, possibly through receptor internalization, thereby contributing to the temporal specificity of melatonin in modulating circadian rhythms.
Physiological concentrations of melatonin mimicking the nocturnal surge decreased the number and internalized recombinant MT 2 melatonin receptors expressed in neuronal-and glial-like immortalized rat SCN2.2 cells and in non-neuronal CHO cells. Reductions in MT 2 receptor number after exposure of CHO cells to either a physiological or supraphysiological concentration of melatonin were recoverable, but a portion of this recovery was dependent on new protein synthesis. A correlation between reductions in specific 2-[ 125 I ]-iodomelatonin binding and receptor internalization after exposure to melatonin was also observed in both the CHO and rat SCN2.2 cells. The fact that a portion of the recovery was protein synthesis-dependent suggests that some of the internalized MT 2 melatonin receptors were targeted for degradation, while another portion of the receptors were directed to a recycling pathway. Furthermore, the observation that the recovery was greater after exposure to 300 pM melatonin compared with 10 nM suggested that this higher concentration may have served as a stronger stimulus targeting a larger proportion of the receptors for degradation. After internalization, many G-proteincoupled receptors (GPCR) are targeted to endosomes, then degraded or recycled back to the cell surface; however, the molecular mechanisms mediating this sorting process remains to be determined (21) . GPCRs are often degraded after prolonged exposure to agonists (i.e., hours) and is associated with slow or incomplete recovery (22) . For example, recovery of 125 I-ET1 binding to the endothelin B receptor after 30 min exposure to ET1 (100 nM) reaches control values after 4 h and is cycloheximide dependent (23) . Tight binding of endothelin to the receptor (K i ϳ59 pM) after internalization may target the receptor for degradation (23) . Melatonin also has picomolar affinity for the MT 2 melatonin receptor (3, 11, 24) and therefore may remain bound after internalization of the receptor and in some way target a portion of the internalized receptor pool to degradation. Internalization induced by supraphysiological concentrations of melatonin could contribute to prolonged MT 2 receptor desensitization when nonphysiological doses of exogenous melatonin are used for the treatment of circadian disfunctions (25) . G i -coupled receptors, however, show wide variability in their ultimate fates after internalization. For example, the D2 dopamine receptor is rapidly internalized (t 1/2 Յ5 min) and recycled back to the plasma membrane (t 1/2 Յ30 min) (26) . Both M 2 muscarinic and ␦-opioid receptors are rapidly internalized but the M 2 muscarinic receptor requires several hours to recover and a portion of this recovery is protein synthesis dependent (27) , while the ␦-opioid is down-regulated by at least 50% (28) . Recovery of 2-[
125 I ]-iodomelatonin binding to MT 2 melatonin receptors after exposure to melatonin takes at least 8 h to reach control levels and appears to involve receptor internalization followed by receptor degradation and recycling back to the membrane. This dynamic internalization and subsequent recycling suggests physiologically that the MT 2 melatonin receptor may follow a time-dependent diurnal rhythm of desensitization during long exposure to the hormone at night and a resensitization during the day when melatonin levels are at their lowest. Maximum receptor responsiveness would then coincide with the periods of melatonin sensitivity to phase-shift circadian rhythms at the beginning of the night (29, 30) .
A physiological concentration of melatonin mimicking the nocturnal secretion of the hormone decreased MT 2 melatonin receptor density, but not MT 1 , in SCN2.2 cells transiently expressing either receptor. Immortalized SCN2.2 cells express components of the mammalian circadian clock (31) , circadian rhythms of metabolic activity and gene expression (18, 32) , and functional melatonin receptors (5) . This cell line is endowed with endogenous melatonin receptors that are functionally coupled to the inhibition of forskolinstimulated cAMP formation and protein kinase stimulation (5, 19, 31) . Thus, the SCN2.2 cell line appears to be an appropriate in vitro model of the native SCN. In SCN2.2 cells, the differential regulation of MT 1 and MT 2 melatonin receptor number and trafficking by physiological concentrations of melatonin mirrors that observed in non-neuronal mammalian cells (33) . This finding is significant because it suggests that when the mammalian melatonin receptors are expressed in a cell in which endogenous MT 1 and MT 2 melatonin receptors are present, regulatory mechanisms may mediate receptor desensitization and internalization similar to what is observed in the CHO-MT 1 and CHO-MT 2 cells (34 (35) and in cultured chick astrocytes (36) .
Prolonged exposure of endogenous MT 2 melatonin receptors to a physiological concentration of melatonin mimicking the nocturnal secretion of the hormone desensitized endogenous MT 2 melatonin receptors in the native rat SCN and in an immortalized SCN2.2 cell line. In the rat native SCN in vitro, activation of MT 2 melatonin receptors, through a PKC-dependent signaling cascade, phase-shift the peak of the circadian rhythm of neuronal firing both at dawn and dusk (4, 13, 20) . In the rat in vivo, however, melatonin only phase-shifts the circadian rhythm of locomotor activity at dusk (14) . It is likely that the lack of a melatoninmediated phase shift at dawn in the rat in vivo is due to desensitization of MT 2 melatonin receptors in the SCN by circulating endogenous melatonin secreted during the night. Thus, when the in vivo situation was recapitulated in the rat SCN brain slice in vitro by administration of exogenous melatonin mimicking the concentration and length of the nocturnal secretion in vivo, the phase shift at dawn was prevented. A similar treatment paradigm in the SCN2.2 cells also desensitized the MT 2 -mediated activation of PKC. In this cell line, there is a rhythmic oscillation of basal PKC activity, and melatonin activates PKC activity via MT 2 receptors at windows of sensitivity equivalent to the periods of sensitivity described for melatonin (i.e., dawn ϳ CT 9 -11; dusk ϳ23-2) (19). These windows of sensitivity roughly correlate with the specific times when melatonin phase-shifts the circadian rhythm of neuronal firing in the rat SCN in vitro (i.e., dawn and dusk) (4, 13) . Together these results suggest that the nightly secretion of melatonin in vivo likely desensitizes endogenous MT 2 melatonin receptors in the rat SCN shaping the periods of sensitivity and determining when the biological clock is sensitive to a melatonin signal.
Melatonin, the ubiquitous hormone of darkness, should also induce desensitization of endogenous MT 2 melatonin receptors by physiological nocturnal levels and contribute to defining the periods of sensitivity of the biological clock in other mammals, including humans. Our results suggest that reduced sensitivity of the biological clock to exogenous melatonin at dawn should correlate with nocturnal plasma melatonin levels, which are known to differ among mammalian species. In humans, nocturnal circulating serum melatonin levels are similar to those reported in the rat (ϳ50 -60 pg/mL) (8) . In support of our results, administration of a single oral dose of melatonin to humans at dawn does not phase-shift circadian rhythms of core body temperature, heart rate, or dim light melatonin onset/offset (37) . Melatonin administration to humans for 4 consecutive days at dawn did phaseshift the circadian rhythm of dim light melatonin onset/offset, but the magnitude of this shift was smaller than the one observed when the hormone was given at dusk (30) . Although the low efficacy of melatonin to phase-shift circadian rhythms in humans when given at dawn may be attributed to the relatively weak zeitgeber properties of this hormone, we cannot exclude melatonin receptor desensitization due to nocturnal serum melatonin which is known to vary among individuals (ϳ72 to 269 pM or 17 to 62 pg/ml) (38) . This receptor desensitization may manifest itself as either diminished or abolished phase-shifting responses at dawn. In C3H/ HeN mice, melatonin phase advances and phase delays by 1 h circadian rhythms of wheel running activity when administered at dusk (CT 9 -11) and dawn (CT24 -CT2) (29) , respectively. The apparent lack of desensitization of the melatonin-mediated delays at dawn is possibly related to the low levels of circulating nocturnal melatonin in this species (ϳ10 -20 pg/mL) (39) compared with the levels in the rat and human (8, 38) . The functional sensitivity of endogenous MT 2 melatonin receptors in the mammalian SCN, and hence the effectiveness of exogenous melatonin to phase-shift circadian rhythms, may reflect individual differences in circulating melatonin levels.
In conclusion, our results are the first to demonstrate that physiological concentrations of melatonin desensitized endogenous MT 2 melatonin receptors, possibly without affecting the sensitivity of endogenous MT 1 receptors (34) . Physiologically, we propose that MT 2 melatonin receptor desensitization in the SCN may contribute to determining the temporal sensitivity profile of the mammalian biological clock to a melatonin signal (30) . It follows that variations in the amplitude of the circadian rhythm of melatonin secretion could desensitize endogenous MT 2 melatonin receptors at inappropriate times, preventing desired melatonin-mediated circadian phase shifts or entrainment (40) . Together, these results suggest that therapeutic doses of melatonin reaching supraphysiological circulating levels could desensitize endogenous MT 2 melatonin receptors at critical periods of sensitivity (i.e., dusk and/or dawn), and therefore affect phase shifts by subsequent doses and/or produce detrimental side effects (41) . This could potentially prevent desired circadian phase shifts by exogenous melatonin for the treatment of circadian disorders as those observed in advance or delay sleep phase syndrome, jet lag, shift work, seasonal affective, and other mood disorders (25, 37, 40) . Thus, our finding of feedback regulation by melatonin in the SCN to mediate phase shifts through MT 2 melatonin receptors has important implications for a range of physiological and pharmacological contexts.
